MEDIPOST will supply drug substance and retain manufacturing rights, while exclusive rights for Japanese market will be managed by Teikoku Seiyaku.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback